XTL Biopharma Fights for Nasdaq Life After 'Public Shell' Judgment

RAMAT GAN, ISRAEL – February 27, 2026 – XTL Biopharmaceuticals Ltd. is facing an existential threat to its public market presence after receiving a delisting determination from Nasdaq. The exchange operator has labeled the company a "public shell," asserting it no longer has a viable operating business, a move that could see its American Depositary Shares (ADSs) removed from the Nasdaq Capital Market as early as next week.

In a press release issued today, the Ramat Gan-based IP portfolio company confirmed it received a letter from Nasdaq's Listing Qualifications Department on February 25. The company has announced its intention to appeal the decision before a Nasdaq Hearings Panel, a move that will temporarily halt the delisting process.

A Cascade of Compliance Failures

The "public shell" designation is the most severe in a series of compliance issues that have plagued XTL in recent months. Nasdaq's determination stems directly from the court-ordered liquidation of XTL's wholly-owned subsidiary, The Social Proxy Ltd., on February 22, 2026. According to Nasdaq, the collapse of this subsidiary means XTL is left without an active business, raising concerns that the company's securities could be "subject to market abuses" and that investors have no clarity on its future operations.

This critical blow comes on top of two other unresolved compliance deficiencies. On December 20, 2025, Nasdaq formally notified XTL that its ADSs had failed to maintain the minimum $1.00 bid price required for continued listing. A month later, on January 20, 2026, the company received another warning for failing to meet the minimum stockholders' equity requirement of $2.5 million.

While XTL was still within the standard compliance period to address the bid price rule, Nasdaq's letter stated that these financial shortcomings serve as "additional and separate bases for delisting." The convergence of these three issues—operational, financial, and market valuation—paints a stark picture of a company in deep distress, fighting a multi-front battle for survival on a major U.S. exchange. Should the company fail to request a hearing by March 4, trading of its ADSs will be suspended on March 6.

The Unraveling of an Operating Business

The trigger for Nasdaq's most serious charge was the formal insolvency of The Social Proxy Ltd. An Israeli court ordered the full liquidation of the web data company after determining it was insolvent with no reasonable prospect of rehabilitation. The subsidiary had filed for insolvency proceedings just days prior, a move that effectively dismantled XTL's only operating arm.

The financial fallout from the liquidation is still being assessed by XTL. A key uncertainty is the fate of an approximately $1.5 million intercompany loan that XTL had extended to its subsidiary. The recoverability of this loan is now in doubt, dependent on the proceeds generated from the liquidation, which are now under the control of a court-appointed trustee. The loss of this subsidiary not only erased XTL's operational footprint but also potentially punched another hole in its already strained balance sheet, exacerbating the very stockholders' equity problem that Nasdaq had previously flagged.

A Strategic Pivot Under Fire

Ironically, the delisting notice arrived just as XTL was attempting a dramatic strategic pivot aimed at resolving its financial woes and securing a new operational future. On January 13, the company announced a binding agreement to acquire 85% of NeuroNOS Ltd., a private company developing therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology.

The NeuroNOS deal was positioned as a transformative move. The subsidiary of Beyond Air, Inc., holds FDA Orphan Drug Designations for two of its candidates and is backed by prominent scientists, including two Nobel Laureates. For XTL, the acquisition was intended to provide a new, promising operational core in the high-growth autism therapeutics market. Crucially, management had stated that the acquisition, coupled with a planned private placement of up to $2 million, was their plan to cure the stockholders' equity deficiency and demonstrate a viable path forward to Nasdaq.

In a race against the clock, XTL convened a shareholder meeting on February 24—just one day before the Nasdaq letter was dated—where all proposals related to the NeuroNOS acquisition and the associated financing were approved. However, this shareholder approval appears to have been too little, too late for Nasdaq staff. The exchange's delisting determination, which focused squarely on the February 22 liquidation of The Social Proxy, suggests that the yet-to-be-closed NeuroNOS acquisition was not considered sufficient to constitute a replacement operating business at the time of their review.

The Fate of a Promising IP Portfolio

Lost in the corporate turmoil is the fate of XTL's foundational asset: its intellectual property for hCDR1, a novel compound for treating Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome. For years, this IP has been the cornerstone of the company's value proposition. hCDR1 has undergone extensive preclinical and clinical testing, including a Phase II trial involving over 400 patients that, while missing its primary endpoint, showed encouraging signals on a key secondary endpoint.

The company has positioned itself as an IP holding company aiming to sublicense these assets to larger pharmaceutical partners for late-stage development. The market for new Lupus treatments is significant, with few new therapies approved in recent decades. However, the ability to attract a strategic partner and negotiate favorable terms is heavily dependent on corporate stability and access to capital markets.

The current delisting threat severely jeopardizes the future of this promising asset. A delisting from Nasdaq would relegate the company's shares to over-the-counter markets, drastically reducing liquidity, investor visibility, and the ability to raise capital. This would make it exponentially more difficult for XTL to fund its own operations, let alone find and support a partner to advance hCDR1 through the costly final phases of clinical trials, leaving the potential therapy stranded within a struggling corporate entity. The company's appeal to the Nasdaq panel will likely hinge on its ability to convince them that the planned acquisition of NeuroNOS represents a credible and immediate path to becoming a substantive operating company once again, thereby preserving the potential value of its long-held intellectual property.